MIRA Pharmaceuticals (MIRA) announced data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of ...

Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, ...

MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in ...

MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...

Animal disease models are non-human animals bearing pathologies that share features with a human disease. Disease models can either exist naturally or be induced artificially and are used for ...

A research paper by scientists at The Second Affiliated Hospital of Zhejiang University School of Medicine presented the ...

Key Laboratory for Food Microbial Technology of Zhejiang Province, School of Food Science and Biotechnology, Zhejiang Gongshang University, Xiasha, Hangzhou, Zhejiang 310018, PR China ...

Introduction: Diabetic macular edema (DME) is a major cause of vision loss in the sick with diabetic retinopathy. The occurrence of DME is closely related to the breakdown of neurovascular coupling; ...

TABLE 1. Summary of the differential responses of NaV proteins in dorsal root ganglia neurons and microlglia cells in spinal dorsal horns toward cilostazol treatments in streptozotocin-induced type I ...